Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M158,611Revenue $M24,890Net Margin (%)45.5Z-Score9.1
Enterprise Value $M162,003EPS $7.4Operating Margin %58.6F-Score8
P/E(ttm))18.4Cash Flow Per Share $4.3Pre-tax Margin (%)56.7Higher ROA y-yY
Price/Book11.510-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales8.35-y EBITDA Growth Rate %12.5Current Ratio2.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %176ROA % (ttm)35.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)72.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,509ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 103.830%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.3)
$ 103.830%New holding, 612500 sh.612,500
GILDJean-Marie Eveillard 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 103.830%Add 328672%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 103.830%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 103.830%Add 6.1%218,945
GILDRay Dalio 2014-12-31 Add0.22%$89.45 - $114.22
($103.4)
$ 103.830%Add 122.47%537,321
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 103.830%Add 24.68%802,803
GILDJohn Burbank 2014-12-31 Add0.06%$89.45 - $114.22
($103.3)
$ 103.830%Add 212.68%37,750
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 103.830%Sold Out0
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 103.830%Sold Out0
GILDMariko Gordon 2014-12-31 Sold Out -0.05%$89.45 - $114.22
($103.3)
$ 103.830%Sold Out0
GILDDavid Dreman 2014-12-31 Sold Out -0.02%$89.45 - $114.22
($103.3)
$ 103.830%Sold Out0
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 103.836%Add 42.59%206,350
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 103.836%Add 42.28%664,223
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 103.836%New holding, 2388 sh.2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 103.836%Add 219.9%12,073
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 103.836%New holding, 4800 sh.4,800
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 103.836%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 103.836%Reduce -76.79%379,200
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 103.836%Reduce -30.96%241,521
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD Jean-Marie Eveillard 2014-12-311,315,0880.090.3+328672%
GILD Leon Cooperman 2014-12-31612,5000.040.96New Buy
GILD John Burbank 2014-12-3137,75000.09+212.68%
GILD Ray Dalio 2014-12-31537,3210.040.4+122.47%
GILD Joel Greenblatt 2014-12-311,009,4620.070.77+51.98%
GILD John Rogers 2014-12-31802,8030.050.87+24.68%
GILD Julian Robertson 2014-12-31533,9110.049.9+20.27%
GILD Ronald Muhlenkamp 2014-12-31218,9450.014.1+6.1%
GILD Ken Fisher 2014-12-31771,5010.050.15+1.06%
GILD - CALLJean-Marie Eveillard 2014-12-311,20000
GILD Mario Gabelli 2014-12-3142,60000.02
GILD Dodge & Cox 2014-12-314,51000-6.04%
GILD David Dreman 2014-12-31000Sold Out
GILD Ken Heebner 2014-12-31000Sold Out
GILD Mariko Gordon 2014-12-31000Sold Out
GILD Vanguard Health Care Fund 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-02-17Sell70,000$103.010.5view
WOLD OLSEN PERDirector 2015-02-06Buy10,000$99.923.61view
Whitley Richard JamesDirector 2015-02-02Sell5,000$105.67-2.03view
Alton Gregg HEVP, Corp & Med Affairs 2015-02-02Sell12,000$105.73-2.08view
Washington Robin LEVP, CFO 2015-02-02Sell33,192$105.38-1.76view
Carter Paul RutherfordEVP Commercial Ops 2015-02-02Sell2,000$106.15-2.47view
MARTIN JOHN CChairman and CEO 2015-02-02Sell150,000$105.43-1.8view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-01-15Sell70,000$98.475.14view
Alton Gregg HEVP, Corp & Med Affairs 2015-01-08Sell5,000$100.892.62view
Carter Paul RutherfordEVP Commercial Ops 2015-01-08Sell1,000$100.882.63view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
    1 Feb 23 2015 
    1 Feb 23 2015 
    Tiger Management’s Julian Robertson Buys Apple, Netflix, Illumina, Sells Alibaba, EBay, MasTec Feb 17 2015 
    8 Strong Recommendations for 2015 Feb 13 2015 
    ? Feb 11 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
    Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 


    More From Other Websites
    These are the most profitable Nasdaq biotech companies Feb 27 2015
    Gilead Sciences: 'HIV Succession Plan Coming Into Focus' Feb 27 2015
    ImmunoVaccine Up 24% On Deal With Gilead Sciences Feb 27 2015
    Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India Feb 27 2015
    Who Might Buy Puma Biotechnology? Feb 27 2015
    Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing... Feb 26 2015
    Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing... Feb 26 2015
    Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV Feb 26 2015
    Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic... Feb 26 2015
    Health Care Stocks Flexing Their Muscle Feb 26 2015
    How Gilead Avoids Billions in U.S. Taxes on Its $1,000-a-Pill Drug Feb 26 2015
    Gilead dodges billions in taxes as money rolls in from hepatitis C drugs Feb 26 2015
    Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Feb 26 2015
    Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic... Feb 26 2015
    Omega Advisors opens a new position in Gilead Sciences Feb 26 2015
    Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
    Gilead Sciences: Despite Dividend, Still Room For Growth Feb 26 2015
    Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally... Feb 25 2015
    Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally... Feb 25 2015
    Is A Renaissance In Surging Biotechs Underway? Feb 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK